EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study

Tsutomu Yoshihara iD, Takaomi Kessoku, Tomohiro Takatsu, Noboru Misawa, Keiichi Ashikari, Akiko Fuyuki, Hidenori Ohkubo, Takuma Higurashi, Michihiro Iwaki, Takeo Kurihashi, Machiko Nakatogawa, Koji Yamamoto und 4 weitere

Neurogastroenterology & Motility · 2024

DOI: 10.1111/nmo.14938 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Neurogastroenterology & Motility, 2024. Verfasst von Tsutomu Yoshihara und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Constipation, Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background This study aimed to evaluate the efficacy and safety of linaclotide in patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS‐C) who did not respond to treatment with magnesium oxide (MgO). Method s This study was designed as a multicenter, open‐label, single‐arm, exploratory study. Patients with CC or IBS‐C who took MgO and those meeting the medication initiation criteria were administered linaclotide at a daily dosage of 500 μg for 12 weeks. The primary endpoint was a change in the Japanese version of the Patient Assessment of Constipation Quality of Life (JPAC‐QOL) score from baseline, which was evaluated by using a paired t ‐test. Key Results The patients' mean age (± standard deviation) was 67.6 ± 13.82 years. The full analysis set included 61 patients. The JPAC‐QOL total score was 1.60 at baseline and 0.70 at 12 weeks, with a significant mean change of −0.89 ± 0.721 ( p < 0.001). Several secondary endpoints also showed improvement. The frequency of spontaneous bowel movement (SBM) and complete SBM increased by 2.70 ± 7.254 ( p < 0.01) and 2.81 ± 5.254 times, respectively ( p < 0.001). The Bristol Stool Form Scale, abdominal bloating severity, and straining severity scores improved by 1.33 ± 1.274 ( p < 0.001), −0.16 ± 0.563 ( p < 0.05), and −0.46 ± 0.795 ( p < 0.001) points, respectively. The safety analysis set included 65 patients, 7 of whom had diarrhea, which improved with dose reduction and drug withdrawal. Conclusion & Inferences The study was conducted in an older adult population, similar to real clinical practice. Linaclotide may be an option for treating CC that shows an inadequate response to conventional therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ConstipationPeptidesHumansMaleFemaleMiddle AgedAgedTreatment OutcomeChronic DiseaseQuality of LifeGuanylyl Cyclase C AgonistsAged, 80 and overIrritable Bowel SyndromeAdultGastrointestinal Agents

Stichwörter der Autor:innen

chronic conditionconstipationirritable bowel syndromemagnesium oxidemulticenter studyolder adultsquality of life

Substanzen

linaclotidePeptidesGuanylyl Cyclase C AgonistsGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan.
  • Department of Internal Medicine, Kanagawa Dental University Yokohama Clinic, Yokohama, Kanagawa, Japan.
  • Department of Internal Medicine, NamikiKoiso-medical Clinic, Yokohama, Kanagawa, Japan.
  • Department of Palliative Medicine, Yokohama City University Hospital, Yokohama, Kanagawa, Japan.
  • Department of Palliative Medicine, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan.
  • Department of Gastroenterology, International University of Health and Welfare Graduate School of Medicine, Narita, Chiba, Japan.

ORCID-Profile: Tsutomu Yoshihara, Atsushi Nakajima

Förderung

  • Astellas Pharma

Zitieren

APA

Yoshihara, T., Kessoku, T., Takatsu, T., Misawa, N., Ashikari, K., Fuyuki, A., Ohkubo, H., Higurashi, T., Iwaki, M., Kurihashi, T., Nakatogawa, M., Yamamoto, K., Terada, I., Tanaka, Y., Morita, M., & Nakajima, A. (2024). Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14938

Vancouver

Yoshihara T, Kessoku T, Takatsu T, Misawa N, Ashikari K, Fuyuki A, et al. Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study. Neurogastroenterology & Motility. 2024. doi:10.1111/nmo.14938

BibTeX
@article{Yoshihara2024,
  author = {Yoshihara, Tsutomu and Kessoku, Takaomi and Takatsu, Tomohiro and Misawa, Noboru and Ashikari, Keiichi and Fuyuki, Akiko and Ohkubo, Hidenori and Higurashi, Takuma and Iwaki, Michihiro and Kurihashi, Takeo and Nakatogawa, Machiko and Yamamoto, Koji and Terada, Izuru and Tanaka, Yusuke and Morita, Masataka and Nakajima, Atsushi},
  title = {Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study},
  journal = {Neurogastroenterology & Motility},
  year = {2024},
  doi = {10.1111/nmo.14938}
}
Kostenlos starten →